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Dendritic cells (DCs) can regulate all elements of the immune system, and therefore are an ideal target for vaccination. During
the last two decades, as a result of extensive research, DCs became the primary target of antitumor vaccination as well. A critical
issue of antitumor vaccination is the phenotype of the dendritic cell used. It has been recently shown that several nuclear hormone
receptors,andamongstthemthelipid-activatednuclearreceptorandperoxisomeproliferator-activatedreceptorgamma(PPARγ),
have important roles in eﬀecting the immunophenotype of human dendritic cells. It regulates primarily lipid metabolism and via
thisitinﬂuencestheimmunophenotypeofDCsbyalteringlipidantigenuptake,presentation,andalsootherimmunefunctions.In
this review, we summarize the principles of antitumor vaccination strategies and present our hypothesis on how PPARγ-regulated
processes might be involved and could be exploited in the design of vaccination strategies.
Copyright © 2008 A. Gy¨ ongy¨ osi and L. Nagy. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. DENDRITIC CELLS IN TUMORS
Dendritic cells (DCs) were discovered in mouse spleen by
Ralph Steinman and Zanvil Cohn in 1973 [1]. Immature
dendritic cells (IDCs) are sentinels of the immune system,
continuously monitoring peripheral tissues for invaders,
capture and process antigens, and migrate to the draining
lymph nodes where they present peptides to naive Treg
cells (T cells) and activate them [2]. The full activation of
T cells requires special peptide-MHCI or peptide-MHCII
complexes and additional signals from DCs in the form
of various costimulatory molecules and cytokines. Further-
more, activated CD4+ T cells could be polarized to T helper
1 (Th1) and T helper 2 (Th2) subtypes. These processes
are dependent on the cytokines interleukin-12 (IL-12), IL-
4, and IL-10 secreted by mature DCs (MDCs). In response
to IL-12, T cells polarize to Th1 and enhance CD8+ cytotoxic
T-cell response against tumor cells or pathogens, while IL-
4- and IL-10-activated Th2 cells promote humoral immune
response and/or tolerance. Another important point is that
DCs can induce T-cell tolerance to self-antigens and via this
prevent and reduce autoimmune diseases.
Importantly, it appears that tumor tissues have char-
acteristic immune environments with distinct DC subset
distributions. Diﬀerent DC subset localization within the
compartments of tumor has been reported in colorectal
cancer and oral squamous cell carcinoma patients. Dad-
abayev et al. investigated the inﬁltration pattern of DCs in
human colorectal tumor samples analyzed with S100 and
HLA class II DC markers. S100+ and CD1a+ DCswerefound
in tumor epithelium, in parallel with intraepithelial CD4+
or CD8+ T-cell inﬁltration and suggested increased disease-
free survival, while HLA class II+ cells were observed in
the stromal compartment, correlated with adversed outcome
of the tumor [3]. Later they utilized CD208 (DC-LAMP)
marker for marking MDCs and proved that CD208+ DCs
were detectable in the peritumoral area, and inﬁltration
of MDCs into tumor epithelium was correlated also with
decreased patient survival [4]. In primary squamous cell
carcinomapatients,IDCsandMDCswerecharacterizedwith2 PPAR Research
distinct tissue localization patterns. Immature Langerhans
cells (LCs) and DC-SIGN+ interstitial DCs were found
inside the tumor tissue while the number of mature
CD208+ DCs was limited. Moreover, CD123+ plasmacytoid
DC representation in the tumor area was correlated with
poor survival [5]. Importantly, DCs interact with tumor
cells and cytokines produced by tumor cells or immune
cells inﬂuence DC function and maturation. The tumor
microenvironment aﬀects DC diﬀerentiation from CD14+
monocytes and haematopoietic precursors promoting an
early and dysfunctional maturation of DCs. Several reports
described reduced the number of DC in peripherial blood,
tumor tissues, and draining lymph nodes in cancer patients.
Partial maturation of DCs by tumor-derived factors like IL-
10, vascular endothelial growth factor (VEGF), and TGF-β
induces self-tolarence and promotes conversion of naive T
cellstoregulatorTcells,favoringdevelopmentofsuppressive
T cells. Presence of tolerogenic T cells in tumor beds
induces local immune suppression and alters the function of
anticancer eﬀector T cells. These cells, isolated from draining
lymph nodes of patients with pancreas or breast cancer
secreteIL-10andTGF-β,preventactivatedCD4 + CD25− and
CD8+ eﬀector T cells, and suppress tumor-speciﬁc immune
response [6]. Apart from the fact that DCs are involved in
activation of Treg, there is an increasing amount of evidence
about T cells, which can be recruited into tumors and aﬀect
DC development. Decreased CD80 and CD86 cell surface
markers by T cells lead to reduced T-cell stimulatory ability
of DCs [7, 8]. Immunosuppressive B7-3/4 molecules are
upregulated on DCs upon DC-Treg interaction reserving a
possiblefeedbacklooptogeneratemoreregulatoryTcells[9,
10]. Another immunosuppressive cycle is the conversion of
DCs by Treg-secreted INF-γ and CTLA-4 into an indolamine
2, 3-dioxigenase (IDO) expressing cells which induce Treg
generation and eﬀector T-cell apoptosis [11, 12].
Classically, CD4+ T cells have been categorized into
Th1, Th2, Treg, and Th17 subsets. However, TGF-β has
a crucial role in Treg and Th17 cell development, the
dichotomy of Treg/Th17 is dependent on IL6. Only a few
pieces of evidence has been reported on the presence and
regulation of Th17 cells by IL-2 in human cancer and
experimental tumors. Muranski et al. reported that tumor-
speciﬁc Th17 polarized cells mediated successful treatment
of large established tumor in cutaneous melanoma-bearing
mice. The therapeutic eﬀe c to ft h ec e l l sw a sd e p e n d e n to n
their INFγ production [13].
Modulating factors released by the tumor environment
cause defective functional maturation of DCs and aﬀect
the diﬀerentiation of immature myeloid-derived suppress-
ing cells (MDSCs). The portion of MDSC is signiﬁcantly
increased in spleen, peripheral blood, and bone marrow of
tumor-bearing patients and correlates with tumor progres-
sion [14–16].
In conclusion, DCs are one of the potent regulator cells
in tumor development. The eﬀects of DCs in cancer patients
are contraversial: several reports demonstrated that myeloid-
derived MDCs induce eﬀective antitumor immune response
and tumor regression. In spite of this, the suppressive tumor
environment can alter the properties of DCs. The functional
defects of DCs have an essentional role in cancer patient
to impede succesful antitumor immune response. These
tolerogenic DCs function as tumor-promoting cells. The
future challenge of anticancer-based therapies is to overcome
DC tolerogenecity and to reduce their negative eﬀects in
tumor progression.
2. DENDRITIC CELL-BASED CANCER THERAPY
It is clear that however in low number DCs are present
in tumors and can be used to elicit antitumor immune
response. The challenge and goal of anticancer therapy is to
elicit an eﬀective cellular immune response against tumor
cells and evoke clinical response in treated patients with
negligible side eﬀects. The discovery of isolation techniques
and methods for diﬀerentiating DCs in vitro gave us the
possibility to generate DCs that could be loaded by tumor-
speciﬁc antigens or peptides. In this therapeutic approach,
one can deﬁne DC-vaccine as a DC loaded with tumor-
speciﬁc antigen. The ﬁrst DC-based clinical trial against
B-cell lymphoma was reported by Hsu et al. [17]. One
important question in DC vaccination is to decide whether
t ou s ea ne xv i v oo ri nv i v ov a c c i n a t i o ns t r a t e g y .T h ee x
vivoapproaches (see Figure 1) allow to monitor the quality
of the cells during the diﬀerentiation procedure, analyze cell
surface markers, the proper maturation state, cell viability,
or subtype speciﬁcity of DCs by FACS analysis. It is also
possible to evaluate the eﬀective tumor antigen-speciﬁc T-
cell response by ELISpot, mixed leukocyte reaction (MLR)
before targeted DCs are introduced back to the patient.
The possible sources of human DCs are CD34+ precursors,
hematopoetic progenitors, and monocytes, isolated from
blood by cytopheresis, adherent techniques or magnetic-
basedimmunoselection,orimmunodepletion[18–20].IDCs
can be diﬀerentiated from peripheral blood-derived mono-
cytes in vitro in the presence of GM-CSF and IL-4 [18,
20]. Alternatively, DC precursors can be isolated from
human peripheral blood, but for eﬀective anticancer therapy
one has to obtain high amount of targetable DCs. In a
clinical trial, FLT-3 ligand-expanded DCs were prepared
from the blood of colon and nonsmall cells of lung cancer
patients. Because of the limited blood DC number, patients
underwent FLT-3 treatment before DC isolation. As a result,
three times more PBMC was obtained from these patients
after standardized leukopheresis as compared to control
patients.Theisolatedpatient-derivedDCsshowedimmature
CD83−/CD40low/CD80low/CD86low phenotype, but after two
days in culture, cells started to express CD83, elevated levels
of CD86 and CCR7 proteins, which reﬂect MDC phenotype
and migration capacity [21]. DC-vaccine studies utilize DCs
loaded with peptide fragments or whole proteins providing
an opportunity to present all potential peptide sequences of
the antigen to recognize even more speciﬁc T-cell clones and
tumor lysates exogenously [22]. Alternatively, one can target
DCs endogenously with antigen-coded mRNA or cDNA
[23]. After loading IDCs with tumor-speciﬁc antigens, it
is very important to add adequate maturation agents (e.g.,
proinﬂammatorycytokines,LPS,CD40L)toensurethatDCs
achieve their maximum migratory capacity to the lymphA. Gy¨ ongy¨ osi and L. Nagy 3
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Figure 1: Generalschemeofanticancervaccination.Dendriticcellprogenitors(eitherCD34+ orCD14+ cells)areobtainedusingcytopheresis.
Cells are diﬀerentiated using cytokines GM-CSF and IL-4. Immature dendritic cells are loaded with tumor lysate, peptides, or expression
vector. DC maturation is induced and DCs are reinjected to patient.
nodes, otherwise only a small portion of antigen-loaded
DCs could migrate to the site of the naive T-cell activation.
Following quality control steps, the generated DC vaccines
have to be reinjected into the patients. An important issue is
also the DC injection site. DC vaccines could be reinjected
to patients by intravenous, subcutaneous, intradermal, or
intralymphatic injections. In a clinical study, the eﬃciency
of diﬀerent injection sites was compared by Fong et al. [24].
According to their results, the intradermal or intralymphatic
administration was more eﬀective compared to intravenous
injection. In general, DC delivery via the skin is preferable
to intravenous injection. Combining the diﬀerent routes
of reinjections may be beneﬁcial, depending on the tumor
localization. Most of the early phase I clinical trials, using
the ex vivo approach, have not shown long-term tumor
regression or improved survival. Probably it is mostly due
to the fact that in these studies the researchers selected
only advanced-stage cancer patients who were immonosup-
pressed by recurrent tumors or by chemotherapy. However,
an in vitro approach could provoke Th1 cell response in
metastatic malignant melanoma [25].
As far as the migratory capacity of DCs is concerned, less
than 5% of the MDCs reach the lymph nodes after intrader-
mic injection [26]. Therefore, it would be more beneﬁcial
to activate and target DCs within the host. In this case,
we are not concerned with cell isolation or diﬀerentiation
protocols, but rather DC-initiated tumor-speciﬁc immune
responses have to be monitored inside the body. Monoclonal
antibodies and fusion construct can be used for more
productive tumor antigen delivery directly into the DCs
and probably the cells do not need to be cultured in vitro.
Many vaccination studies target DC-speciﬁc c-type lectin
receptors for eﬃcient targeting of tumor antigens into the
cells.Thesereceptorsbindtoparticularself-ornonself-sugar
patterns by means of their carbohydrate recognition domain
(CRD) and have roles in endocytotic antigen uptake [27].
One of them, DEC205/DC205, is expressed at high levels by
MDC in mice, but human B cells, NK cells, monocytes, and
macrophages also express this receptor [28]. Bozzacco et al.
designed a fusion monoclonal antibody construct by taking
the light and heavy chain coding cDNA sequence of an anti-
DEC205antibodyandbyinsertingdiﬀerentgagp24peptides
at the carboxy terminus of the heavy chain. According to
their results, these antibodies increased antigen presentation
in the treated HIV-infected patients. They could further
demonstrate DC-primed cross-presentation of internalized,
nonreplicating proteins to MHCI complexes inducing CD8+
T-cell activity [29]. These results support the feasibility
of engineering tumor-speciﬁc peptide fragment into DC-
targeted antibodies against various types of cancer in vivo.
3. THE ROLE OF THE PPARγ RECEPTOR IN
DENDRITIC CELLS
3.1. PPARγ-alteredphenotypeofDCs
Nuclear hormone receptors are ligand-activated transcrip-
tion factors. There are three diﬀerent PPAR isoformes in
the human body and these show distinct tissue-speciﬁc
distribution with diﬀerent physiological functions. PPARα is4 PPAR Research
most highly expressed in the liver, skeletal muscle, kidney,
and heart, and it regulates fatty acid oxidation [30]. PPARδ
shows a ubiquiter distribution while PPARγ expression
can be detected in various cell types like adipocytes,
macrophages, and DCs. The receptor was initially described
in mouse adipose tissue [31] and its role in myeloid
development was shown by Nagy and Tontonoz in 1998
[32, 33]. PPARγknockout mice are lipodystrophic and die
of placental defect, showing the essential regulatory role for
the receptors in embryonic diﬀerentiation [34]. Moreover,
high level of PPARγ expression can be detected in monocyte-
derived macrophages in atheroscleric lesions [33]. PPAR
receptors heterodimerize with retinoid X receptors (RXRs)
in the nucleus and bind to certain receptor-speciﬁc response
elements (PPREs) in the promoter or enhancer regions of
their target genes [35]. The PPRE contains direct repeat
sequences separated by one base pair (DR1). Endogenous
or exogenous ligands bind into the ligand-binding domain
(LBD) of PPARγ and modulate PPARγ-mediated gene
expression. PPARγ can be activated by components of the
oxidized low-density lipoprotein (oxLDL) and prostaglandin
derivate (e.g.,15d-PGJ2) [32, 36]. Ligand activation of the
receptor induces the expression of CD36 scavenger receptor
which in turn leads to oxLDL uptake of macrophages and
this metabolic process can lead to foam cell formation [32].
From these studies, we know that PPARγ regulates fatty
acid uptake into the cell by induced cell surface receptors
and it also promotes lipid storage and accumulation. Beside
this fundamental regulatory role in metabolism, the receptor
also functions as a key modulatory factor in macrophage
immune function [37]. Earlier microarray data suggested
that the PPARγ gene is upregulated during monocyte-to-
DC diﬀerentiation [38]. According to our experiments and
those of others, the receptor is immediately upregulated in
cultured DCs, while it is barely detectable in monocytes [39].
We have shown that the transcription factor in this system
is active, because synthetic agonists induce dose-dependent
gene expression of the bone ﬁde PPARγ target gene FABP4
in IDCs [39, 40]. Through global gene expression analysis,
we found that PPARγ-activated genes involved primarily in
the ﬁrst 6 hours are involved primarly in lipid metabolism
and transport (CD36, LXRα, and PGAR). Genes, coupled to
theimmuneregulatoryroleofhumanDCs,wereupregulated
onlyfor24and120hoursafterligandtreatment.Itispossible
that immunophenotype of DCs could be altered by PPARγ
activation indirectly through activation of lipid metabolism
and signaling pathways [41].
In terms of DC-based vaccination therapy, the most
important question is how PPARγ activation might eﬀect the
DC-initiated immune responses and DC phenotype. PPARγ
expression was ﬁrst detected in murine DCs by Faveeuw
et al. and they reported that there is a PPARγ receptor-
dependent inhibition of IL-12 secretion of IDCs and MDCs
[42]. Furthermore, it was also shown that PPARγ ligand
activation caused anti-inﬂammatory cytokine production
in macrophages [37]. These ﬁndings support the idea that
PPARγ might have an essential role in the APC-based DC-
vaccine therapies. The DC-secreted IL-12 is indispensable
for Th1 cell promotion and CD8+ T-cell activation. Earlier
publications by Gosett et al. and Nencioni et al. assessed
that PPARγ ligand activation alters the immunogenicity
of human monocyte-derived DCs [43, 44]. During DC
maturation, costimulatory molecules (CD40, CD80, and
CD86) are upregulated on the surface of DCs [2]. Some
bacterial products, such as LPS, are able to induce signals
via TLR receptors or CD40 molecules induce IL-12 secretion
of DCs. They have also found that upon ligand activation
of PPARγ, the phenotype and cytokine expression patterns
of the cells were changed [43]. PPARγ ligands altered iDC-
speciﬁc surface markers involved in APC function. The
CD83 activation marker expression in treated MDCs was
uneﬀected, which means that PPARγ ligand-activated cells
showed mature phenotype. After ligand activation, elevated
CD86 protein level was detected on the surface of MDCs.
They also showed that activation of PPARγ inhibits the
secretion of IL-12p70 active form into the supernatant by
MDCs while the levels of IL-6 and IL-10 were unchanged.
Furthermore, chemokines involved in Th1 cell recruitment
(IP-10, RANTES, and MIP1α), were also decreased after
ligand treatment in the same study. Nencioni et al. later
characterized the eﬀects of PPARγ on DC maturation and
found that ligand activation reduced the surface expression
of CD1a molecule in a concentration-dependent manner,
resulting in an unusual phenotype of diﬀerentiated IDCs
[44]. Lower levels of IL-10, IL-6, and TNFα cytokines were
measured upon ligand treatment. PPARγ agonist impaired
the allogenic T-cell stimulating capacity in MLR assays
and the secreted INFγ concentration was also reduced.
T-cell activation capacity could not be restored by IL-12
administration suggesting that the impaired T-cell activation
of MDCs was not only due to lack of IL-12 expression but
also to other eﬀects that modulate DC maturation process
were involved.
In conclusion, the PPARγ ligand-activated cells not
only impede the naive T cell to Th1 cell diﬀerentiation,
but these cells also showed decreased antigen-speciﬁc T-
cell response. Appel et al. reported that important anti-
inﬂammatory eﬀects of the receptor as ligand activation of
thePPARγ receptorsinhibitedtheLPS-activatedMAPkinase
and NF-κB proinﬂammatory signaling pathways, probably
due to transrepression mechanism in DCs that subvert IL-12
expression [45].
Flow cytometry measurements performed by some of
us largely supported the phenotypic results reviewed above
[39]. Furthermore, when treated DCs with PPARγ,w e
detected that enhanced endocytosis in the form of enhanced
latex bead uptake and ligand-treated cells were CD1a−.
We could not detect any diﬀerences in case of HLA-ABC
molecule expression, suggesting that the MHCI-mediated
peptide antigen presentation capacity of the cell is probably
not aﬀected [46]. As reported by Angeli, PPARγ inhibits
the expression of CCR7 on the surface of MDCs and this
decreased the migration of DCs in mice. In this model,
TNFα-induced epidermal LC motility from epidermis to
dermal lymph nodes was reduced by PPARγ ligand treat-
ment.Theyalsofoundthatligand-activatedPPARγ impaired
the steady-state migration of DCs from the mucosal to
the thoracic lymph nodes, but the maximal inhibitoryA. Gy¨ ongy¨ osi and L. Nagy 5
eﬀect was detected at a considerably high concentration
of the PPARγ agonist rosiglitazone (10μM) that suggested
receptor-independent eﬀects [47].
Summarizing these data, PPARγ activation in DCs
prevented IL-12 secretion, lowered CD80/CD86 ratio, and
probably shifted naive T-cell diﬀerentiation toward Th2
cells. According to our own experiments, PPARγ agonist
rosiglitazone at 2.5μM concentration did not decrease the
activation of allogeneic T cell and INFγ production [39].
So far, no one was able to detect Th2 response in MLR in
response to PPARγ ligand activation.
3.2. TheroleofPPARγ inCD1d-mediatedlipid
antigenpresentation
Szatmari et al. provided evidence that PPARγ activation
could eﬀect the lipid antigen presentation capacity of
monocyte-derived DCs through upregulated expression of
CD1d molecule on the surface of DCs [39]. This ﬁnding
links PPARγ to invariant natural killer T (iNKT) cells.
After isolation, monocytes fail to express CD1 group I
molecules (CD1a, b, c) but the CD1a protein is upregulated
during monocyte-to-IDC diﬀerentiation [20]. Inversely, the
CD1 group II molecule CD1d is expressed at high levels
on monocytes and downregulated on the surface of DCs
[39]. Induced signaling pathways are able to regulate CD1d
gene expression and lipid metabolism upon PPARγ ligand
treatment [41]. Utilizing PPARγ agonist treatment, Gogolak
et al. could induce the expression of CD1d molecules
along with downregulation of CD1a at both mRNA and
protein levels [48]. Later we established that PPARγ ligand
activation enhanced indirectly the CD1d expression by
turning on endogenous lipophilic ligand synthesis in the
DCs through activation of the expression of retinol dehydro-
genase 10 (RDH10) and retinaldehyde dehydrogenase type
2 (RALDH2) enzymes, which are involved in retinol and
retinal metabolism and endogenous all-trans retinoic acid
(ATRA) production from retinol [46]. The intracellularly
synthesized ATRA induced CD1d and other retinoic acid
receptor alpha (RARα) target genes in DCs. We looked
at the functional role of PPARγ-induced retinoid-regulated
CD1d expression on DC surface. DCs pulsed with synthetic
alpha-galactosilceramide (αGalCer) ligand for 24 hours
elevated iNKT cell expansion and INFγ secretion [39, 41].
As CD1d-mediated lipid antigen presentation is essential
for iNKT cell activation, we could conclude that PPARγ-
induced CD1d expression can be translated to the increased
activation and proliferation of iNKT cells under these in
vitro conditions [39]. Our results suggest that combination
of PPARγ activator ligands along with αGalCer during the
diﬀerentiation of DCs might be beneﬁcial in iNKT-based
adoptive transfer therapy (see Figure 2).
4. CD1d-RESTRICTED iNKT CELLS IN
CANCER THERAPY
4.1. iNKTcell-basedanticancereffectsin
animalmodels
Besides DCs and T cells, there are other important cell
types contributing to antitumor immunity. iNKT cells are
a unique T-lymphocyte population. These cells share both
NK (CD161) and T-cell-speciﬁc markers (TCRs) on their
surfaces. iNKT cells have restricted T-cell receptors (TCRs):
in mice, the most frequently expressed α-chain rearrange-
ment is Vα14-Jα1 8w h i l eh u m a nN K Tc e l l se x p r e s sV α24-
Jα18/Vβ11 TCRs (reviewed by Godfrey and Kronenberg
[49]).For iNKT activation, it is essential to interact withcells
displaying the evolutionarily conserved CD1d, nonclassical
antigen-presenting molecules that present glicolipids in the
context of hydrophobic antigen binding to these cells [50,
51]. αGalCer is the most frequently used lipid ligand for
iNKT activation. It is derived from a marine sponge.
αGalCer has shown antimetastatic activity in various
experimentaltumormodels(e.g.,B16melanoma,Lewislung
carcinoma,FBL-3erytroleukemia,Colon26,andRMA-S3LL
tumor cells) in vivo [52–54]. This eﬀect of the compound
was tested in CD1d−/−, Ja281−/− RAG−/− NKT mice, which
have no iNKT cells and in NK-depleted wild-type mice. The
results indicated that the antitumor eﬀect of the glycolipid
was abolished on all of the three tested genetic backgrounds
in mice and the αGalCer-mediated antimetastatic function
likely acts through iNKT cell activation and NK-like eﬀec-
tor function [52]. Adoptive transfer experiments provided
further proof for the key role of iNKT cell-secreted INFγ
in the antimetastatic role of αGalCer in mice. Furthermore,
activation and proliferation of NK cells downstream to
iNKT activation, and subsequent INFγ production was also
required to be essential for antimetastatic cytotoxic activity
in vitro and in vivo [55, 56]. αGalCer activates iNKT cells,
whichproduceINFγ,andsecondaryactivatesNKcells.These
activatedNKcellshavebeenimplicatedalsointheregulation
of angiogenesis during tumor development. The αGalCer
treatment inhibits the subcutaneous tumor growth, tumor-
induced angiogenesis, and epithelial cell proliferation, which
are required for tumor vessel formation [57]. Later it has
been established that αGalCer treatment, in combination
with IL-21, prolonged and elevated the NK cell cytotoxicity,
maturing NK cells into perforine-expressing cells by IL-21.
Moreover, this combination inhibited spontaneous tumor
metastases. Presentation of αGalCer by DC to iNKT cells
in contrast to soluble compound injection was even more
eﬀective in the suppression of metastasis formation [58].
Similar successful antitumor eﬀects of αGalCer-pulsed DC
have been published by Toura et al. using B16 melanoma
liver metastasis and lung metastasis of LLC model in vivo.
Beside the inhibition of metastatic nodule formation in these
tissues, αGalCer-DC administration also has a signiﬁcant
beneﬁcial eﬀect in the regression of established nodules
[59, 60].
4.2. iNKTcellsinhumancancertherapy
Human Vα24+ iNKT cells also mediate αGalCer-dependent
antitumor activity by perforin-dependent cytotoxic lysis
against Daudi lymphoma and other various cell lines [53,
61]. Others demonstrated eﬀective direct iNKT-mediated
cytotoxicityonlyagainstCD1d+ celllinessuchasU937,while
CD1d− cell lines were killed only after CD1d transfection6 PPAR Research
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Figure 2: T h em o l e c u l a rb a s i sf o rt h ep o t e n t i a lu s eo fP P A R γ-programed dendritic cells during tumor vaccination. DC progenitors are
diﬀerentiated in the presence of PPARγ agonists. A PPARγ-programed DC showed increased CD1d expression. In the presence of αGalCer,
thetreatedDCiscapableofinducingiNKTcellexpansion.TheadoptivelytransferediNKTscaninduceactivationofiDCsandIL-12secretion
in cancer patients. This can lead to improved ability to kill tumor cells.
into the cells. NKT cells provoked NK cell-induced cytotoxi-
tity by IL-2 and INFγ secretion [62].
The crosstalk between innate and adaptive immunity
was established in several anticancer studies. This linkage
could be mediated via reciprocal interaction between iNKT
cells and iDCs. Upon αGalCer activation, iNKT cells express
CD40L [63]. The CD40 ligand binds to the CD40 molecules
of DCs and triggers IL-12 expression and secretion by the
DCs. The produced IL-12 generates a positive feedback and
induces INFγ secretion by the iNKTs [63, 64]. The secondary
activation of DCs leads to NK, CD4+, and CD8+ T-cell
activation by standard activation of memory T cells and
adaptive immune response against peptides presented by
DCs [65–67].
The fact that αGalCer-loaded DC could trigger iNKT
expansion and mediate antitumor immune response in sev-
eralinvitroexperimentsandinvivoantimetastaticmodelsin
mice supported the notion that using αGalCer-pulsed DCs
for iNKT activation in cancer patients in situ might induce
an eﬀective anticancer therapy. Other alternative approach
could be the adoptive transfer of in vitro expanded and
activated iNKT cells to patients.
The number of NKT cells in cancer patients is signif-
icantly lower compared to healthy volunteers. Giaccone et
al. showed the disappearance of iNKT cells after 24 hours
of αGalCer administration from the peripheral blood of
patients and only transient iNKT activation was registered
in some individuals [68]. Others found quantitative defects
in iNKT cell-derived INFγ production among patients
with advanced prostate cancer [69]. Showing that NK cells
were able to respond to IL-12, those cells could secrete
increased levels of INFγ demonstrating the selective loss ofA. Gy¨ ongy¨ osi and L. Nagy 7
INFγ-secreting capacity of iNKT cells in patients [69]. As
it was expected from mouse experiments, Chang et al. were
able to expand the number of iNKT cells for more than a
month in all treated patients, proving that αGalCer-pulsed
MDCs could be more eﬀective than using αGalCer-pulsed
IDC or the soluble compound [70]. However, the levels of
IL-12p40andIL-10intheserumwereelevatedafterthetreat-
ment and iNKT cells showed reduced-INFγ secretion. The
future challenge of this type of tumor therapy is to induce
extended iNKT number and activity. One possible approach
is to use additional pharmacological ligands upon cancer
therapies. It has been shown that the thalidomide analogue,
lenalidomide (LEN), enhanced the predominant iNKT cell
expansion in vitro and in vivoin response to αGalCer-loaded
DC. LEN elicits higher level of INFγ secretion in response to
αGalCer-loaded DC, suggesting that LEN might be restoring
the INFγ-producing activity of iNKT cells in cancer patients
[71]. Alternative possibility is the adoptive transfer method:
in phase I clinical trial, adoptive transferred iNKTs were
used in patients with malignancy to increase the number
of iNKT cells [72]. They expanded iNKT cells in vitro in
the presence of IL-2 and αGalCer. The activated iNKT cells
showed cytotoxic activity against PC-13 and Daudi human
cancer cell lines. Reinjection of activated iNKT cell into the
patients enhanced the level of INFγ secreting iNKT cells in
the peripheral blood from day one up to two weeks [72].
5. DENDRITIC CELL PPARγ IN ANTICANCER THERAPY
Despite the enormous research eﬀort, cancer is still a
signiﬁcant clinical problem as well as basic science problem.
However, immunotherapy opened up some possibility in
the ﬁght against cancer. General APC features of DCs are
capturing antigens in the periphery, processing, and enhanc-
ing MHC-peptide complex presentation capacity to naive T
cells. These phenomena highlighted possible roles for DCs
in anticancer therapy. However, DC-based vaccination often
does not elicit clinical responses and fails to ensure long-
time tumor regression in patients with malignant tumors.
One reason for this failure could be the immunosuppressed
state of the patient, for example, due to chemotherapy in
the therapeutical history. Recently, we have identiﬁed a new
target gene, ABCG2, which is transcriptionally regulated
by PPARγ in DCs. ABCG2 transporters modify the drug
resistance against anticancer agent of PPARγ agonist-treated
DCs. PPARγ has a protective function in these cells, and
using PPARγ-speciﬁc ligands during in vitro diﬀerentiation
could revert the xenobiotics-induced toxicity in DCs [73].
Due to the fact that we did not ﬁnd reduced capacity
of DCs to activate T cell in MLR assays, we concluded that
ligand activation does not suppress DC-mediated peptide
antigen presentation. For eﬀective anticancer therapy, one
should provoke adaptive immune response against tumor-
speciﬁc peptides presented by DCs. In mouse experi-
ments, simultaneously added αGalCer and peptide-loaded
DCs induced CD4/CD8 T-cell-speciﬁc anticancer immune
response mediated by iNKT cell. In case of human patients,
αGalCer-loaded DCs could not induce adaptive immunity,
partlybecauseoftheineﬀectiveINFγ secretionbyiNKTcells.
Pharmacological approaches like LEN may solve this prob-
lem. The ability of PPARγ to upregulate CD1d expression on
DCs raises the possibility to use receptor agonists in iNKT-
based adoptive transfer treatments.
Many features of DCs, which are critical during DC-
vaccination design, are aﬀected by PPARγ. Reduced migra-
tory capacity, inhibited IL-12 cytokine production, inade-
quate Th1 and CD8+ T-cell response, and presumed gener-
ation of IL-10-producing tolerogenic DC could inﬂuence the
outcome of DC-based vaccination therapies against cancer.
Based mainly on these in vitro results, activation of the
PPARγ receptor in tumor peptide-pulsed DCs could be less
beneﬁcial in terms of in vivo vaccination strategies. At the
same time, increased phagocytic capacity, increased CD1d
expression, and iNKT activation potential are useful features
of PPARγ-programed DCs. In spite of the vast amount of
in vitro obtained results on the potential role of PPARγ in
DCs, the most controversial issue remains open: whether
synthetic PPARγagonists have signiﬁcant modifying eﬀects
on antitumor immune response in vivo or not. Further
in vivo studies are needed to clarify the receptor-speciﬁc
immunomodulatory eﬀects of PPARγ ligands (agonists or
antagonists) in cancer patients. For that, the use of siRNA-
based gene-silencing techniques or DC-speciﬁc PPARγ,K O
animal models would probably be useful.
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